Die Eigentümerstrukturen börsennotierter deutscher Unternehmen haben sich in den letzten Jahren deutlich verändert. Von besonderem Interesse ist dabei das Phänomen der gemeinsamen Eigentümerstrukturen, das international mit dem Begriff "Common Ownership" bezeichnet wird. Dabei werden...

In our paper targets, by setting a reserve price, screen acquirers on their (expected) ability to generate merger-speci?c synergies. Both empirical evidence and many common merger models suggest that the di?erence between high- and low-synergy mergers becomes smaller during booms. This implies...

We present an ex-post analysis of the effects of GDF's acquisition of Suez in 2006 created one of the world's largest energy companies. We perform an econometric analysis, based on Difference-in-Difference techniques on the market for trading on the Zeebrugge gas hub in Belgium. Removing...

In our paper targets, by setting a reserve price, screen acquirers on their (expected) ability to generate merger-speci?c synergies. Both empirical evidence and many common merger models suggest that the di?erence between high- and low-synergy mergers becomes smaller during booms. This implies...

Die Bereitstellung eines sicheren und wirksamen Impfstoffs gegen Covid-19 ist von zentraler Bedeutung für die Aufhebung der Eindämmungsmaßnahmen im öffentlichen Leben. Um den Zugang zu Impfstoffen zu sichern, schließen Regierungen mit Impfstoffunternehmen spezielle Verträge, "Advance...

We investigate patterns in common ownership networks between firms that are active in the US pharmaceutical industry for the period 2004-2014. Our main findings are that "brand firms" - i.e. firms that have R&D capabilities and launch new drugs - exhibit relatively dense common ownership...

Common ownership - where several firms are (partially) owned by the same investors - and its impact on product market competition has recently drawn much attention. This paper focuses on its implications for market entry. Specifically, we consider the entry decisions of generic pharmaceutical...

We investigate patterns in common ownership networks between firms that are active in the U.S. pharmaceutical industry for the period 2004–2014. Our main findings are that “brand firms”—that is, firms that have research and development capabilities and launch new drugs—exhibit...

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...